Search research articles
Contact Us
Filters
Showing results (31-40 of 126) with videos related to
Page
of 13
Sort By:
Drug and Alcohol Dependence
|
September 6, 2003
Understanding US addiction physicians' low rate of naltrexone prescription
Tami L Mark, Henry R Kranzler, Xue Song
JAMA
|
July 10, 2019
Association Between Medicare and FDA Policies and Prior Authorization Requirements for Buprenorphine Products in Medicare Part D Plans
Tami L Mark, William Parish, Gary A Zarkin
Psychiatric Services (Washington, D.C.)
|
September 3, 2009
Datapoints: psychotropic drug prescriptions by medical specialty
Tami L Mark, Katharine R Levit, Jeffrey A Buck
Journal of Substance Abuse Treatment
|
December 26, 2012
Psychiatric and medical comorbidities, associated pain, and health care utilization of patients prescribed buprenorphine
Tami L Mark, Joan Dilonardo, Rita Vandivort, et al.
Journal of Cataract and Refractive Surgery
|
April 26, 2002
Axial length in applanation tonometry
Harry H Mark, Kim P Robbins, Tami L Mark
Technology in Cancer Research & Treatment
|
September 12, 2008
The benefits and challenges of using computer-assisted symptom assessments in oncology clinics: results of a qualitative assessment
Tami L Mark, Gina Johnson, Barry Fortner, et al.
The American Journal of Managed Care
|
March 17, 2009
The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures
Tami L Mark, Teresa B Gibson, Kimberly A McGuigan
Journal of Substance Abuse Treatment
|
November 7, 2006
Factors affecting detoxification readmission: analysis of public sector data from three states
Tami L Mark, Rita Vandivort-Warren, Leslie B Montejano
JAMA Network Open
|
April 21, 2020
Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries
Tami L Mark, William J Parish, Gary A Zarkin
Health Affairs (Project Hope)
|
March 18, 2026
US National Spending On Mental Health And Substance Use Disorder Treatment Driven By Case Growth, 2000-21
Tami L Mark, Lasanthi Fernando, Peter Shieh, et al.
Page
of 13
Search research articles
Search
Showing results (31-40 of 126) with videos related to
Sort By:
Page
of 13
Drug and Alcohol Dependence
|
September 6, 2003
Understanding US addiction physicians' low rate of naltrexone prescription
Tami L Mark, Henry R Kranzler, Xue Song
JAMA
|
July 10, 2019
Association Between Medicare and FDA Policies and Prior Authorization Requirements for Buprenorphine Products in Medicare Part D Plans
Tami L Mark, William Parish, Gary A Zarkin
Psychiatric Services (Washington, D.C.)
|
September 3, 2009
Datapoints: psychotropic drug prescriptions by medical specialty
Tami L Mark, Katharine R Levit, Jeffrey A Buck
Journal of Substance Abuse Treatment
|
December 26, 2012
Psychiatric and medical comorbidities, associated pain, and health care utilization of patients prescribed buprenorphine
Tami L Mark, Joan Dilonardo, Rita Vandivort, et al.
Journal of Cataract and Refractive Surgery
|
April 26, 2002
Axial length in applanation tonometry
Harry H Mark, Kim P Robbins, Tami L Mark
Technology in Cancer Research & Treatment
|
September 12, 2008
The benefits and challenges of using computer-assisted symptom assessments in oncology clinics: results of a qualitative assessment
Tami L Mark, Gina Johnson, Barry Fortner, et al.
The American Journal of Managed Care
|
March 17, 2009
The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures
Tami L Mark, Teresa B Gibson, Kimberly A McGuigan
Journal of Substance Abuse Treatment
|
November 7, 2006
Factors affecting detoxification readmission: analysis of public sector data from three states
Tami L Mark, Rita Vandivort-Warren, Leslie B Montejano
JAMA Network Open
|
April 21, 2020
Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries
Tami L Mark, William J Parish, Gary A Zarkin
Health Affairs (Project Hope)
|
March 18, 2026
US National Spending On Mental Health And Substance Use Disorder Treatment Driven By Case Growth, 2000-21
Tami L Mark, Lasanthi Fernando, Peter Shieh, et al.
Page
of 13